{
    "name": "ropeginterferon alfa 2b",
    "comment": "Rx",
    "other_names": [
        "Besremi",
        "ropeginterferon alfa-2b-njft"
    ],
    "classes": [
        "Immunomodulators"
    ],
    "source": "https://reference.medscape.com/drug/besremi-ropeginterferon-alfa-2b-4000128",
    "pregnancy": {
        "common": [
            "Insufficient human data are available on use in pregnant females to identify a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes",
            "Animal studies assessing reproductive toxicity have not been conducted",
            "Based on mechanism of action and the role of interferon alfa in pregnancy and fetal development, fetal harm may occur and should be assumed to have abortifacient potential when administered to pregnant females",
            "Verify pregnancy in females of reproductive potential before initiating"
        ],
        "specific": [
            {
                "type": "Disease-associated maternal and/or embryofetal risk",
                "description": [
                    "Untreated polycythemia vera during pregnancy is associated with adverse maternal outcomes such as thrombosis and hemorrhage",
                    "Adverse pregnancy outcomes associated with polycythemia vera include increased risk for miscarriage"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Females of reproductive potential: Use effective contraception during treatment and for at least 8 weeks after final dose"
                ]
            },
            {
                "type": "Infertility",
                "description": [
                    "Based on its mechanism of action, therapy can cause disruption of the menstrual cycle",
                    "No animal fertility studies have been conducted"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence in human or animal milk, effects on breastfed children, or effects on milk production",
            "Advise females not to breastfeed during treatment and for 8 weeks after final dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Risk of serious disorders",
                    "description": [
                        "Interferon alfa products may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders",
                        "Closely monitor patients with periodic clinical and laboratory evaluations",
                        "Withdraw therapy in patients with persistently severe or worsening signs or symptoms of these conditions; in many, but not all cases, these disorders resolve after stopping therapy"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Presence or history of severe psychiatric disorders, particularly severe depression, suicidal ideation, or suicide attempt",
                "Hypersensitivity to interferons including interferon alfa-2b or any inactive ingredients",
                "Moderate or severe (Child-Pugh B or C) hepatic impairment",
                "History or presence of active serious or untreated autoimmune disease",
                "Immunosuppressed transplant recipients"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Endocrine toxicity has occurred; do not use in patients with active serious or untreated endocrine disorders associated with autoimmune disease; evaluate thyroid function in patients who develop symptoms suggestive of thyroid disease during therapy; discontinue in patients who develop endocrine disorders that cannot be adequately managed during treatment",
                "Cardiovascular toxicity (eg, cardiomyopathy, myocardial infarction, atrial fibrillation, coronary artery ischemia) reported; closely monitor for cardiovascular toxicity during therapy; avoid use with severe or unstable cardiovascular disease, (eg, uncontrolled hypertension, congestive heart failure (NYHA class â‰¥2), serious cardiac arrhythmia, significant coronary artery stenosis, unstable angina) or recent stroke or myocardial infarction",
                "Decreased peripheral blood counts have occurred; these toxicities may include thrombocytopenia (increasing the risk of bleeding), anemia, and leukopenia (increasing the risk of infection)",
                "Hypersensitivity reactions may occur; may include serious, acute hypersensitivity reactions (eg, urticaria, angioedema, bronchoconstriction, anaphylaxis); if such reactions occur, discontinue therapy and institute appropriate medical therapy immediately",
                "Pancreatitis reported; symptoms may include nausea, vomiting, upper abdominal pain, bloating, and fever; may experience elevated lipase, amylase, WBC, or altered renal/hepatic function; interrupt treatment in patients with possible pancreatitis and evaluate promptly; consider discontinuation with confirmed pancreatitis",
                "Fatal and serious ulcerative or hemorrhagic/ischemic colitis have occurred; symptoms may include abdominal pain, bloody diarrhea, and fever; discontinue if signs or symptoms develop; colitis may resolve within 1-3 weeks of stopping treatment ",
                "Pulmonary toxicities may occur; toxicity may manifest as dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis obliterans, interstitial pneumonitis, pulmonary hypertension, and sarcoidosis; discontinue if pulmonary infiltrates or pulmonary function impairment",
                "Ophthalmologic toxicity reported; advise patients to have eye examinations before and during treatment; evaluate eye symptoms promptly and discontinue if new or worsening eye disorders,especifically in those patients with a retinopathy-associated disease such as diabetes mellitus or hypertension",
                "Hyperlipidemia, hypertriglyceridemia, or dyslipidemia occurred; monitor serum triglycerides before treatment and intermittently during therapy and manage when elevated",
                "Hepatotoxicity may occur; these toxicities may include increases in serum ALT, AST, GGT and bilirubin; monitor liver enzymes and hepatic function at baseline and during treatment. Reduce dose or discontinue depending on severity; discontinue in patients who develop evidence of hepatic decompensation (eg, jaundice, ascites, hepatic encephalopathy, hepatorenal syndrome, variceal hemorrhage) during treatment",
                "Renal toxicity reported; monitor serum creatinine at baseline and during therapy; avoid use in patients with eGFR <30 mL/min; discontinue if severe renal impairment develops",
                "Dental and periodontal toxicity may occur; these toxicities may include dental and periodontal disorders; advise patients on good oral hygiene and to have regular dental examinations",
                "Dermatologic toxicities (eg, skin rash, pruritus, alopecia, erythema, psoriasis, xeroderma, dermatitis, acneiform hyperkeratosis, hyperhidrosis) reported; consider discontinuing if clinically significant dermatologic toxicity",
                "Advise patients to avoid driving or using machinery if they experience dizziness, somnolence, or hallucination",
                "May cause fetal harm when administered to pregnant females"
            ],
            "specific": [
                {
                    "type": "Depression and suicide",
                    "description": [
                        "Life-threatening or fatal neuropsychiatric reactions have occurred ",
                        "These reactions may occur in patients with and without previous psychiatric illness",
                        "Other CNS effects, including suicidal ideation, attempted suicide, aggression, bipolar disorder, mania, and confusion have been observed with other interferon alfa products",
                        "Contraindicated with history of severe psychiatric disorders, particularly severe depression, suicidal ideation, or suicide attempt",
                        "Closely monitor for any symptoms of psychiatric disorders and consider psychiatric consultation and treatment if such symptoms emerge",
                        "If psychiatric symptoms worsen, discontinue therapy"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Drugs metabolized by CYP450",
                        "Certain proinflammatory cytokines, including interferons, can suppress CYP450 enzymes resulting in increased exposures of some CYP substrates",
                        "Monitor patients on ropeginterferon alfa who are receiving concomitant drugs that are CYP450 substrates with a narrow therapeutic index to inform if dosage modification for these concomitant drugs is necessary",
                        "Myelosuppressive agents",
                        "Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression",
                        "Myelosuppressive agents can produce additive myelosuppression",
                        "Narcotics, hypnotics, or sedatives",
                        "Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity",
                        "Narcotics, hypnotics, or sedatives can produce additive neuropsychiatric side effects"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "abemaciclib",
            "description": {
                "common": "ropeginterferon alfa 2b, abemaciclib.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "acalabrutinib",
            "description": {
                "common": "ropeginterferon alfa 2b, acalabrutinib.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "albendazole",
            "description": {
                "common": "ropeginterferon alfa 2b, albendazole.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "aldesleukin",
            "description": {
                "common": "ropeginterferon alfa 2b, aldesleukin.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "alemtuzumab",
            "description": {
                "common": "ropeginterferon alfa 2b, alemtuzumab.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "allopurinol",
            "description": {
                "common": "ropeginterferon alfa 2b, allopurinol.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "altretamine",
            "description": {
                "common": "ropeginterferon alfa 2b, altretamine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "arsenic trioxide",
            "description": {
                "common": "ropeginterferon alfa 2b, arsenic trioxide.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "ropeginterferon alfa 2b, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "azacitidine",
            "description": {
                "common": "ropeginterferon alfa 2b, azacitidine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "belinostat",
            "description": {
                "common": "ropeginterferon alfa 2b, belinostat.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bendamustine",
            "description": {
                "common": "ropeginterferon alfa 2b, bendamustine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bevacizumab",
            "description": {
                "common": "ropeginterferon alfa 2b, bevacizumab.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bexarotene",
            "description": {
                "common": "ropeginterferon alfa 2b, bexarotene.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "blinatumomab",
            "description": {
                "common": "ropeginterferon alfa 2b, blinatumomab.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bortezomib",
            "description": {
                "common": "ropeginterferon alfa 2b, bortezomib.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bosutinib",
            "description": {
                "common": "ropeginterferon alfa 2b, bosutinib.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppressionMyelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "ropeginterferon alfa 2b, brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "busulfan",
            "description": {
                "common": "ropeginterferon alfa 2b, busulfan.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cabazitaxel",
            "description": {
                "common": "ropeginterferon alfa 2b, cabazitaxel.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "capecitabine",
            "description": {
                "common": "ropeginterferon alfa 2b, capecitabine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "ropeginterferon alfa 2b, carbamazepine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "carboplatin",
            "description": {
                "common": "ropeginterferon alfa 2b, carboplatin.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "carfilzomib",
            "description": {
                "common": "ropeginterferon alfa 2b, carfilzomib.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "carmustine",
            "description": {
                "common": "ropeginterferon alfa 2b, carmustine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "chlorambucil",
            "description": {
                "common": "ropeginterferon alfa 2b, chlorambucil.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "chloramphenicol",
            "description": {
                "common": "ropeginterferon alfa 2b, chloramphenicol.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cidofovir",
            "description": {
                "common": "ropeginterferon alfa 2b, cidofovir.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "ropeginterferon alfa 2b, ciltacabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cisplatin",
            "description": {
                "common": "ropeginterferon alfa 2b, cisplatin.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cladribine",
            "description": {
                "common": "ropeginterferon alfa 2b, cladribine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clofarabine",
            "description": {
                "common": "ropeginterferon alfa 2b, clofarabine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clozapine",
            "description": {
                "common": "ropeginterferon alfa 2b, clozapine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "colchicine",
            "description": {
                "common": "ropeginterferon alfa 2b, colchicine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cyclophosphamide",
            "description": {
                "common": "ropeginterferon alfa 2b, cyclophosphamide.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cytarabine",
            "description": {
                "common": "ropeginterferon alfa 2b, cytarabine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dacarbazine",
            "description": {
                "common": "ropeginterferon alfa 2b, dacarbazine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dactinomycin",
            "description": {
                "common": "ropeginterferon alfa 2b, dactinomycin.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dasatinib",
            "description": {
                "common": "ropeginterferon alfa 2b, dasatinib.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "daunorubicin",
            "description": {
                "common": "ropeginterferon alfa 2b, daunorubicin.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "decitabine",
            "description": {
                "common": "ropeginterferon alfa 2b, decitabine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "desflurane",
            "description": {
                "common": "ropeginterferon alfa 2b and desflurane both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "desvenlafaxine",
            "description": {
                "common": "ropeginterferon alfa 2b and desvenlafaxine both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "deutetrabenazine",
            "description": {
                "common": "ropeginterferon alfa 2b and deutetrabenazine both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dexchlorpheniramine",
            "description": {
                "common": "ropeginterferon alfa 2b and dexchlorpheniramine both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dexmedetomidine",
            "description": {
                "common": "ropeginterferon alfa 2b and dexmedetomidine both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dexrazoxane",
            "description": {
                "common": "ropeginterferon alfa 2b, dexrazoxane.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dichloralphenazone",
            "description": {
                "common": "ropeginterferon alfa 2b and dichloralphenazone both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dichlorphenamide",
            "description": {
                "common": "ropeginterferon alfa 2b and dichlorphenamide both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "difelikefalin",
            "description": {
                "common": "ropeginterferon alfa 2b and difelikefalin both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "difenoxin hcl",
            "description": {
                "common": "ropeginterferon alfa 2b and difenoxin hcl both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dinutuximab",
            "description": {
                "common": "ropeginterferon alfa 2b, dinutuximab.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "diphenoxylate hcl",
            "description": {
                "common": "ropeginterferon alfa 2b and diphenoxylate hcl both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "docetaxel",
            "description": {
                "common": "ropeginterferon alfa 2b, docetaxel.\nEither increases levels of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "doxorubicin",
            "description": {
                "common": "ropeginterferon alfa 2b, doxorubicin.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "doxorubicin liposomal",
            "description": {
                "common": "ropeginterferon alfa 2b, doxorubicin liposomal.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dronabinol",
            "description": {
                "common": "ropeginterferon alfa 2b and dronabinol both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "droperidol",
            "description": {
                "common": "ropeginterferon alfa 2b and droperidol both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "duloxetine",
            "description": {
                "common": "ropeginterferon alfa 2b and duloxetine both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "efavirenz",
            "description": {
                "common": "ropeginterferon alfa 2b and efavirenz both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "entacapone",
            "description": {
                "common": "ropeginterferon alfa 2b and entacapone both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "epirubicin",
            "description": {
                "common": "ropeginterferon alfa 2b, epirubicin.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "eribulin",
            "description": {
                "common": "ropeginterferon alfa 2b, eribulin.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "escitalopram",
            "description": {
                "common": "ropeginterferon alfa 2b, escitalopram.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "estramustine",
            "description": {
                "common": "ropeginterferon alfa 2b, estramustine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ethosuximide",
            "description": {
                "common": "ropeginterferon alfa 2b and ethosuximide both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ethotoin",
            "description": {
                "common": "ropeginterferon alfa 2b and ethotoin both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "etoposide",
            "description": {
                "common": "ropeginterferon alfa 2b, etoposide.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "everolimus",
            "description": {
                "common": "ropeginterferon alfa 2b, everolimus.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "flibanserin",
            "description": {
                "common": "ropeginterferon alfa 2b and flibanserin both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "floxuridine",
            "description": {
                "common": "ropeginterferon alfa 2b, floxuridine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "flucytosine",
            "description": {
                "common": "ropeginterferon alfa 2b, flucytosine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fludarabine",
            "description": {
                "common": "ropeginterferon alfa 2b, fludarabine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fluorouracil",
            "description": {
                "common": "ropeginterferon alfa 2b, fluorouracil.\nEither increases levels of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "ropeginterferon alfa 2b and fosphenytoin both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "gabapentin",
            "description": {
                "common": "ropeginterferon alfa 2b and gabapentin both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "gabapentin enacarbil",
            "description": {
                "common": "ropeginterferon alfa 2b and gabapentin enacarbil both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ganciclovir",
            "description": {
                "common": "ropeginterferon alfa 2b, ganciclovir.\nEither increases levels of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "guanfacine",
            "description": {
                "common": "ropeginterferon alfa 2b and guanfacine both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "haloperidol",
            "description": {
                "common": "ropeginterferon alfa 2b, haloperidol.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hydroxyurea",
            "description": {
                "common": "ropeginterferon alfa 2b, hydroxyurea.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ibritumomab tiuxetan",
            "description": {
                "common": "ropeginterferon alfa 2b, ibritumomab tiuxetan.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ibrutinib",
            "description": {
                "common": "ropeginterferon alfa 2b, ibrutinib.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idarubicin",
            "description": {
                "common": "ropeginterferon alfa 2b, idarubicin.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "ropeginterferon alfa 2b, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "ropeginterferon alfa 2b, ifosfamide.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "imatinib",
            "description": {
                "common": "ropeginterferon alfa 2b, imatinib.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "interferon alfa 2b",
            "description": {
                "common": "ropeginterferon alfa 2b, interferon alfa 2b.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "interferon beta 1a",
            "description": {
                "common": "ropeginterferon alfa 2b, interferon beta 1a.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "interferon beta 1b",
            "description": {
                "common": "ropeginterferon alfa 2b, interferon beta 1b.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "interferon gamma 1b",
            "description": {
                "common": "ropeginterferon alfa 2b, interferon gamma 1b.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "irinotecan",
            "description": {
                "common": "ropeginterferon alfa 2b, irinotecan.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "isoflurane",
            "description": {
                "common": "ropeginterferon alfa 2b and isoflurane both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ixabepilone",
            "description": {
                "common": "ropeginterferon alfa 2b, ixabepilone.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ketamine",
            "description": {
                "common": "ropeginterferon alfa 2b and ketamine both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lenalidomide",
            "description": {
                "common": "ropeginterferon alfa 2b, lenalidomide.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "levetiracetam",
            "description": {
                "common": "ropeginterferon alfa 2b, levetiracetam.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "linezolid",
            "description": {
                "common": "ropeginterferon alfa 2b, linezolid.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisocabtagene maraleucel",
            "description": {
                "common": "ropeginterferon alfa 2b, lisocabtagene maraleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lithium",
            "description": {
                "common": "ropeginterferon alfa 2b and lithium both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lomustine",
            "description": {
                "common": "ropeginterferon alfa 2b, lomustine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "maprotiline",
            "description": {
                "common": "ropeginterferon alfa 2b and maprotiline both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mebendazole",
            "description": {
                "common": "ropeginterferon alfa 2b, mebendazole.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mechlorethamine",
            "description": {
                "common": "ropeginterferon alfa 2b, mechlorethamine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "meclizine",
            "description": {
                "common": "ropeginterferon alfa 2b and meclizine both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "melphalan",
            "description": {
                "common": "ropeginterferon alfa 2b, melphalan.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mercaptopurine",
            "description": {
                "common": "ropeginterferon alfa 2b, mercaptopurine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methadone",
            "description": {
                "common": "ropeginterferon alfa 2b and methadone both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methimazole",
            "description": {
                "common": "ropeginterferon alfa 2b, methimazole.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methohexital",
            "description": {
                "common": "ropeginterferon alfa 2b and methohexital both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methotrexate",
            "description": {
                "common": "ropeginterferon alfa 2b, methotrexate.\nEither increases levels of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methsuximide",
            "description": {
                "common": "ropeginterferon alfa 2b and methsuximide both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "metyrosine",
            "description": {
                "common": "ropeginterferon alfa 2b and metyrosine both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mirtazapine",
            "description": {
                "common": "ropeginterferon alfa 2b and mirtazapine both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mitomycin",
            "description": {
                "common": "ropeginterferon alfa 2b, mitomycin.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mitoxantrone",
            "description": {
                "common": "ropeginterferon alfa 2b, mitoxantrone.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "morphine",
            "description": {
                "common": "ropeginterferon alfa 2b and morphine both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nabilone",
            "description": {
                "common": "ropeginterferon alfa 2b and nabilone both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nefazodone",
            "description": {
                "common": "ropeginterferon alfa 2b and nefazodone both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nelarabine",
            "description": {
                "common": "ropeginterferon alfa 2b, nelarabine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nilotinib",
            "description": {
                "common": "ropeginterferon alfa 2b, nilotinib.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nitrous oxide",
            "description": {
                "common": "ropeginterferon alfa 2b and nitrous oxide both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "obinutuzumab",
            "description": {
                "common": "ropeginterferon alfa 2b, obinutuzumab.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "olaparib",
            "description": {
                "common": "ropeginterferon alfa 2b, olaparib.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "opium tincture",
            "description": {
                "common": "ropeginterferon alfa 2b and opium tincture both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oxaliplatin",
            "description": {
                "common": "ropeginterferon alfa 2b, oxaliplatin.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oxybutynin",
            "description": {
                "common": "ropeginterferon alfa 2b and oxybutynin both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "paclitaxel",
            "description": {
                "common": "ropeginterferon alfa 2b, paclitaxel.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "palbociclib",
            "description": {
                "common": "ropeginterferon alfa 2b, palbociclib.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pazopanib",
            "description": {
                "common": "ropeginterferon alfa 2b, pazopanib.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "peginterferon alfa 2a",
            "description": {
                "common": "ropeginterferon alfa 2b, peginterferon alfa 2a.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pemetrexed",
            "description": {
                "common": "ropeginterferon alfa 2b, pemetrexed.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pentostatin",
            "description": {
                "common": "ropeginterferon alfa 2b, pentostatin.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "perampanel",
            "description": {
                "common": "ropeginterferon alfa 2b and perampanel both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pheniramine",
            "description": {
                "common": "ropeginterferon alfa 2b and pheniramine both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "ropeginterferon alfa 2b and phenobarbital both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phenytoin",
            "description": {
                "common": "ropeginterferon alfa 2b and phenytoin both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ponatinib",
            "description": {
                "common": "ropeginterferon alfa 2b, ponatinib.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "primaquine",
            "description": {
                "common": "ropeginterferon alfa 2b, primaquine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "primidone",
            "description": {
                "common": "ropeginterferon alfa 2b and primidone both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "procarbazine",
            "description": {
                "common": "ropeginterferon alfa 2b, procarbazine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "propofol",
            "description": {
                "common": "ropeginterferon alfa 2b and propofol both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "propylthiouracil",
            "description": {
                "common": "ropeginterferon alfa 2b, propylthiouracil.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pyrimethamine",
            "description": {
                "common": "ropeginterferon alfa 2b, pyrimethamine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rituximab",
            "description": {
                "common": "ropeginterferon alfa 2b, rituximab.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ruxolitinib",
            "description": {
                "common": "ropeginterferon alfa 2b, ruxolitinib.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "scopolamine",
            "description": {
                "common": "ropeginterferon alfa 2b and scopolamine both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sevoflurane",
            "description": {
                "common": "ropeginterferon alfa 2b and sevoflurane both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sirolimus",
            "description": {
                "common": "ropeginterferon alfa 2b, sirolimus.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sodium oxybate",
            "description": {
                "common": "ropeginterferon alfa 2b and sodium oxybate both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sorafenib",
            "description": {
                "common": "ropeginterferon alfa 2b, sorafenib.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "streptozocin",
            "description": {
                "common": "ropeginterferon alfa 2b, streptozocin.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sulfasalazine",
            "description": {
                "common": "ropeginterferon alfa 2b, sulfasalazine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sunitinib",
            "description": {
                "common": "ropeginterferon alfa 2b, sunitinib.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "ropeginterferon alfa 2b, tacrolimus.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tedizolid",
            "description": {
                "common": "ropeginterferon alfa 2b, tedizolid.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "temazepam",
            "description": {
                "common": "ropeginterferon alfa 2b and temazepam both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "temozolomide",
            "description": {
                "common": "ropeginterferon alfa 2b, temozolomide.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "teniposide",
            "description": {
                "common": "ropeginterferon alfa 2b, teniposide.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tetrabenazine",
            "description": {
                "common": "ropeginterferon alfa 2b and tetrabenazine both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "thalidomide",
            "description": {
                "common": "ropeginterferon alfa 2b, thalidomide.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "theophylline",
            "description": {
                "common": "ropeginterferon alfa 2b and theophylline both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "thioguanine",
            "description": {
                "common": "ropeginterferon alfa 2b, thioguanine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "thiotepa",
            "description": {
                "common": "ropeginterferon alfa 2b, thiotepa.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "ropeginterferon alfa 2b, tisagenlecleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tizanidine",
            "description": {
                "common": "ropeginterferon alfa 2b and tizanidine both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tofacitinib",
            "description": {
                "common": "ropeginterferon alfa 2b, tofacitinib.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tolcapone",
            "description": {
                "common": "ropeginterferon alfa 2b and tolcapone both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "topotecan",
            "description": {
                "common": "ropeginterferon alfa 2b, topotecan.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tositumomab",
            "description": {
                "common": "ropeginterferon alfa 2b, tositumomab.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trabectedin",
            "description": {
                "common": "ropeginterferon alfa 2b, trabectedin.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trastuzumab",
            "description": {
                "common": "ropeginterferon alfa 2b, trastuzumab.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trimethobenzamide",
            "description": {
                "common": "ropeginterferon alfa 2b and trimethobenzamide both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "valerian",
            "description": {
                "common": "ropeginterferon alfa 2b and valerian both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vilazodone",
            "description": {
                "common": "ropeginterferon alfa 2b and vilazodone both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vinblastine",
            "description": {
                "common": "ropeginterferon alfa 2b, vinblastine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vincristine",
            "description": {
                "common": "ropeginterferon alfa 2b, vincristine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vinorelbine",
            "description": {
                "common": "ropeginterferon alfa 2b, vinorelbine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vorinostat",
            "description": {
                "common": "ropeginterferon alfa 2b, vorinostat.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ziconotide",
            "description": {
                "common": "ropeginterferon alfa 2b and ziconotide both increase  Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "zidovudine",
            "description": {
                "common": "ropeginterferon alfa 2b, zidovudine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alfentanil",
            "description": {
                "common": "ropeginterferon alfa 2b will increase the level or effect of alfentanil by  Other (see comment). Use Caution/Monitor. Certain proinflammatory cytokines, including interferons, can suppress CYP450 enzymes resulting in increased exposures of some CYP substrates. Therefore, monitor patients who are receiving concomitant drugs that are CYP450 substrates with a narrow therapeutic index from toxicities to such drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amphotericin B cholesteryl sulfate",
            "description": {
                "common": "ropeginterferon alfa 2b will increase the level or effect of amphotericin B cholesteryl sulfate by  Other (see comment). Use Caution/Monitor. Certain proinflammatory cytokines, including interferons, can suppress CYP450 enzymes resulting in increased exposures of some CYP substrates. Therefore, monitor patients who are receiving concomitant drugs that are CYP450 substrates with a narrow therapeutic index from toxicities to such drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amphotericin B deoxycholate",
            "description": {
                "common": "ropeginterferon alfa 2b will increase the level or effect of amphotericin B deoxycholate by  Other (see comment). Use Caution/Monitor. Certain proinflammatory cytokines, including interferons, can suppress CYP450 enzymes resulting in increased exposures of some CYP substrates. Therefore, monitor patients who are receiving concomitant drugs that are CYP450 substrates with a narrow therapeutic index from toxicities to such drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amphotericin B liposomal",
            "description": {
                "common": "ropeginterferon alfa 2b will increase the level or effect of amphotericin B liposomal by  Other (see comment). Use Caution/Monitor. Certain proinflammatory cytokines, including interferons, can suppress CYP450 enzymes resulting in increased exposures of some CYP substrates. Therefore, monitor patients who are receiving concomitant drugs that are CYP450 substrates with a narrow therapeutic index from toxicities to such drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amphotericin B phospholipid complex",
            "description": {
                "common": "ropeginterferon alfa 2b will increase the level or effect of amphotericin B phospholipid complex by  Other (see comment). Use Caution/Monitor. Certain proinflammatory cytokines, including interferons, can suppress CYP450 enzymes resulting in increased exposures of some CYP substrates. Therefore, monitor patients who are receiving concomitant drugs that are CYP450 substrates with a narrow therapeutic index from toxicities to such drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clonidine",
            "description": {
                "common": "ropeginterferon alfa 2b will increase the level or effect of clonidine by  Other (see comment). Use Caution/Monitor. Certain proinflammatory cytokines, including interferons, can suppress CYP450 enzymes resulting in increased exposures of some CYP substrates. Therefore, monitor patients who are receiving concomitant drugs that are CYP450 substrates with a narrow therapeutic index from toxicities to such drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "ropeginterferon alfa 2b will increase the level or effect of cyclosporine by  Other (see comment). Use Caution/Monitor. Certain proinflammatory cytokines, including interferons, can suppress CYP450 enzymes resulting in increased exposures of some CYP substrates. Therefore, monitor patients who are receiving concomitant drugs that are CYP450 substrates with a narrow therapeutic index from toxicities to such drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dihydroergotamine",
            "description": {
                "common": "ropeginterferon alfa 2b will increase the level or effect of dihydroergotamine by  Other (see comment). Use Caution/Monitor. Certain proinflammatory cytokines, including interferons, can suppress CYP450 enzymes resulting in increased exposures of some CYP substrates. Therefore, monitor patients who are receiving concomitant drugs that are CYP450 substrates with a narrow therapeutic index from toxicities to such drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dihydroergotamine inhaled",
            "description": {
                "common": "ropeginterferon alfa 2b will increase the level or effect of dihydroergotamine inhaled by  Other (see comment). Use Caution/Monitor. Certain proinflammatory cytokines, including interferons, can suppress CYP450 enzymes resulting in increased exposures of some CYP substrates. Therefore, monitor patients who are receiving concomitant drugs that are CYP450 substrates with a narrow therapeutic index from toxicities to such drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "disopyramide",
            "description": {
                "common": "ropeginterferon alfa 2b will increase the level or effect of disopyramide by  Other (see comment). Use Caution/Monitor. Certain proinflammatory cytokines, including interferons, can suppress CYP450 enzymes resulting in increased exposures of some CYP substrates. Therefore, monitor patients who are receiving concomitant drugs that are CYP450 substrates with a narrow therapeutic index from toxicities to such drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "divalproex sodium",
            "description": {
                "common": "ropeginterferon alfa 2b will increase the level or effect of divalproex sodium by  Other (see comment). Use Caution/Monitor. Certain proinflammatory cytokines, including interferons, can suppress CYP450 enzymes resulting in increased exposures of some CYP substrates. Therefore, monitor patients who are receiving concomitant drugs that are CYP450 substrates with a narrow therapeutic index from toxicities to such drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ergotamine",
            "description": {
                "common": "ropeginterferon alfa 2b will increase the level or effect of ergotamine by  Other (see comment). Use Caution/Monitor. Certain proinflammatory cytokines, including interferons, can suppress CYP450 enzymes resulting in increased exposures of some CYP substrates. Therefore, monitor patients who are receiving concomitant drugs that are CYP450 substrates with a narrow therapeutic index from toxicities to such drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fentanyl",
            "description": {
                "common": "ropeginterferon alfa 2b will increase the level or effect of fentanyl by  Other (see comment). Use Caution/Monitor. Certain proinflammatory cytokines, including interferons, can suppress CYP450 enzymes resulting in increased exposures of some CYP substrates. Therefore, monitor patients who are receiving concomitant drugs that are CYP450 substrates with a narrow therapeutic index from toxicities to such drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fentanyl intranasal",
            "description": {
                "common": "ropeginterferon alfa 2b will increase the level or effect of fentanyl intranasal by  Other (see comment). Use Caution/Monitor. Certain proinflammatory cytokines, including interferons, can suppress CYP450 enzymes resulting in increased exposures of some CYP substrates. Therefore, monitor patients who are receiving concomitant drugs that are CYP450 substrates with a narrow therapeutic index from toxicities to such drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fentanyl iontophoretic transdermal system",
            "description": {
                "common": "ropeginterferon alfa 2b will increase the level or effect of fentanyl iontophoretic transdermal system by  Other (see comment). Use Caution/Monitor. Certain proinflammatory cytokines, including interferons, can suppress CYP450 enzymes resulting in increased exposures of some CYP substrates. Therefore, monitor patients who are receiving concomitant drugs that are CYP450 substrates with a narrow therapeutic index from toxicities to such drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fentanyl transdermal",
            "description": {
                "common": "ropeginterferon alfa 2b will increase the level or effect of fentanyl transdermal by  Other (see comment). Use Caution/Monitor. Certain proinflammatory cytokines, including interferons, can suppress CYP450 enzymes resulting in increased exposures of some CYP substrates. Therefore, monitor patients who are receiving concomitant drugs that are CYP450 substrates with a narrow therapeutic index from toxicities to such drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fentanyl transmucosal",
            "description": {
                "common": "ropeginterferon alfa 2b will increase the level or effect of fentanyl transmucosal by  Other (see comment). Use Caution/Monitor. Certain proinflammatory cytokines, including interferons, can suppress CYP450 enzymes resulting in increased exposures of some CYP substrates. Therefore, monitor patients who are receiving concomitant drugs that are CYP450 substrates with a narrow therapeutic index from toxicities to such drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "ropeginterferon alfa 2b and isavuconazonium sulfate both decrease  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levothyroxine",
            "description": {
                "common": "ropeginterferon alfa 2b will increase the level or effect of levothyroxine by  Other (see comment). Use Caution/Monitor. Certain proinflammatory cytokines, including interferons, can suppress CYP450 enzymes resulting in increased exposures of some CYP substrates. Therefore, monitor patients who are receiving concomitant drugs that are CYP450 substrates with a narrow therapeutic index from toxicities to such drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "midazolam",
            "description": {
                "common": "ropeginterferon alfa 2b will increase the level or effect of midazolam by  Other (see comment). Use Caution/Monitor. Certain proinflammatory cytokines, including interferons, can suppress CYP450 enzymes resulting in increased exposures of some CYP substrates. Therefore, monitor patients who are receiving concomitant drugs that are CYP450 substrates with a narrow therapeutic index from toxicities to such drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "minoxidil",
            "description": {
                "common": "ropeginterferon alfa 2b will increase the level or effect of minoxidil by  Other (see comment). Use Caution/Monitor. Certain proinflammatory cytokines, including interferons, can suppress CYP450 enzymes resulting in increased exposures of some CYP substrates. Therefore, monitor patients who are receiving concomitant drugs that are CYP450 substrates with a narrow therapeutic index from toxicities to such drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pimozide",
            "description": {
                "common": "ropeginterferon alfa 2b will increase the level or effect of pimozide by  Other (see comment). Use Caution/Monitor. Certain proinflammatory cytokines, including interferons, can suppress CYP450 enzymes resulting in increased exposures of some CYP substrates. Therefore, monitor patients who are receiving concomitant drugs that are CYP450 substrates with a narrow therapeutic index from toxicities to such drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prazosin",
            "description": {
                "common": "ropeginterferon alfa 2b will increase the level or effect of prazosin by  Other (see comment). Use Caution/Monitor. Certain proinflammatory cytokines, including interferons, can suppress CYP450 enzymes resulting in increased exposures of some CYP substrates. Therefore, monitor patients who are receiving concomitant drugs that are CYP450 substrates with a narrow therapeutic index from toxicities to such drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinidine",
            "description": {
                "common": "ropeginterferon alfa 2b will increase the level or effect of quinidine by  Other (see comment). Use Caution/Monitor. Certain proinflammatory cytokines, including interferons, can suppress CYP450 enzymes resulting in increased exposures of some CYP substrates. Therefore, monitor patients who are receiving concomitant drugs that are CYP450 substrates with a narrow therapeutic index from toxicities to such drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "repaglinide",
            "description": {
                "common": "ropeginterferon alfa 2b will increase the level or effect of repaglinide by  Other (see comment). Use Caution/Monitor. Certain proinflammatory cytokines, including interferons, can suppress CYP450 enzymes resulting in increased exposures of some CYP substrates. Therefore, monitor patients who are receiving concomitant drugs that are CYP450 substrates with a narrow therapeutic index from toxicities to such drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thioridazine",
            "description": {
                "common": "ropeginterferon alfa 2b will increase the level or effect of thioridazine by  Other (see comment). Use Caution/Monitor. Certain proinflammatory cytokines, including interferons, can suppress CYP450 enzymes resulting in increased exposures of some CYP substrates. Therefore, monitor patients who are receiving concomitant drugs that are CYP450 substrates with a narrow therapeutic index from toxicities to such drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triazolam",
            "description": {
                "common": "ropeginterferon alfa 2b will increase the level or effect of triazolam by  Other (see comment). Use Caution/Monitor. Certain proinflammatory cytokines, including interferons, can suppress CYP450 enzymes resulting in increased exposures of some CYP substrates. Therefore, monitor patients who are receiving concomitant drugs that are CYP450 substrates with a narrow therapeutic index from toxicities to such drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab and ropeginterferon alfa 2b both increase  immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Owing to potential additive immunosuppressive effects, consider duration of effect and mechanism of action of these therapies if coadministered"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valproic acid",
            "description": {
                "common": "ropeginterferon alfa 2b will increase the level or effect of valproic acid by  Other (see comment). Use Caution/Monitor. Certain proinflammatory cytokines, including interferons, can suppress CYP450 enzymes resulting in increased exposures of some CYP substrates. Therefore, monitor patients who are receiving concomitant drugs that are CYP450 substrates with a narrow therapeutic index from toxicities to such drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "ropeginterferon alfa 2b increases effects of warfarin by unspecified interaction mechanism. Use Caution/Monitor."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Influenza",
            "percent": "59"
        },
        {
            "name": "like illness",
            "percent": "47"
        },
        {
            "name": "Arthralgia",
            "percent": "47"
        },
        {
            "name": "Fatigue",
            "percent": "45"
        },
        {
            "name": "Pruritus",
            "percent": "43"
        },
        {
            "name": "Nasopharyngitis",
            "percent": "41"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "39"
        },
        {
            "name": "Headache",
            "percent": "33"
        },
        {
            "name": "Diarrhea",
            "percent": "29"
        },
        {
            "name": "Hyperhidrosis",
            "percent": "28"
        },
        {
            "name": "Nausea",
            "percent": "27"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "26"
        },
        {
            "name": "Local administration site reactions",
            "percent": "22"
        },
        {
            "name": "Dizziness",
            "percent": "20"
        },
        {
            "name": "Abdominal pain",
            "percent": "20"
        },
        {
            "name": "Depression",
            "percent": "20"
        },
        {
            "name": "Sleep disorder",
            "percent": "18"
        },
        {
            "name": "Leukopenia",
            "percent": "18"
        },
        {
            "name": "Decreased appetite",
            "percent": "16"
        },
        {
            "name": "Alopecia",
            "percent": "16"
        },
        {
            "name": "Edema",
            "percent": "16"
        },
        {
            "name": "Hypertension",
            "percent": "16"
        },
        {
            "name": "Muscle spasms",
            "percent": "16"
        },
        {
            "name": "Neutropenia",
            "percent": "16"
        },
        {
            "name": "Rash",
            "percent": "16"
        },
        {
            "name": "Transaminase elevations",
            "percent": "16"
        },
        {
            "name": "Urinary tract infection",
            "percent": "12"
        },
        {
            "name": "Thrombocytopenia",
            "percent": "12"
        },
        {
            "name": "Vertigo",
            "percent": "10"
        },
        {
            "name": "Atrial fibrillation",
            "percent": null
        }
    ]
}